These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

854 related articles for article (PubMed ID: 27438322)

  • 1. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time: Insights From the ARISTOTLE Randomized Clinical Trial.
    Hijazi Z; Hohnloser SH; Andersson U; Alexander JH; Hanna M; Keltai M; Parkhomenko A; López-Sendón JL; Lopes RD; Siegbahn A; Granger CB; Wallentin L
    JAMA Cardiol; 2016 Jul; 1(4):451-60. PubMed ID: 27438322
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
    Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
    J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial.
    Alexander JH; Andersson U; Lopes RD; Hijazi Z; Hohnloser SH; Ezekowitz JA; Halvorsen S; Hanna M; Commerford P; Ruzyllo W; Huber K; Al-Khatib SM; Granger CB; Wallentin L;
    JAMA Cardiol; 2016 Sep; 1(6):673-81. PubMed ID: 27463942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
    Vinereanu D; Stevens SR; Alexander JH; Al-Khatib SM; Avezum A; Bahit MC; Granger CB; Lopes RD; Halvorsen S; Hanna M; Husted S; Hylek EM; Mărgulescu AD; Wallentin L; Atar D
    Eur Heart J; 2015 Dec; 36(46):3268-75. PubMed ID: 26371113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial.
    Jaspers Focks J; Brouwer MA; Wojdyla DM; Thomas L; Lopes RD; Washam JB; Lanas F; Xavier D; Husted S; Wallentin L; Alexander JH; Granger CB; Verheugt FW
    BMJ; 2016 Jun; 353():i2868. PubMed ID: 27306620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial.
    Avezum A; Lopes RD; Schulte PJ; Lanas F; Gersh BJ; Hanna M; Pais P; Erol C; Diaz R; Bahit MC; Bartunek J; De Caterina R; Goto S; Ruzyllo W; Zhu J; Granger CB; Alexander JH
    Circulation; 2015 Aug; 132(8):624-32. PubMed ID: 26106009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal bleeding in patients with atrial fibrillation treated with Apixaban or warfarin: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Garcia DA; Fisher DA; Mulder H; Wruck L; De Caterina R; Halvorsen S; Granger CB; Held C; Wallentin L; Alexander JH; Lopes RD
    Am Heart J; 2020 Mar; 221():1-8. PubMed ID: 31896036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Echocardiographic Risk Factors for Stroke and Outcomes in Patients With Atrial Fibrillation Anticoagulated With Apixaban or Warfarin.
    Vinereanu D; Lopes RD; Mulder H; Gersh BJ; Hanna M; de Barros E Silva PGM; Atar D; Wallentin L; Granger CB; Alexander JH;
    Stroke; 2017 Dec; 48(12):3266-3273. PubMed ID: 29089455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Hohnloser SH; Hijazi Z; Thomas L; Alexander JH; Amerena J; Hanna M; Keltai M; Lanas F; Lopes RD; Lopez-Sendon J; Granger CB; Wallentin L
    Eur Heart J; 2012 Nov; 33(22):2821-30. PubMed ID: 22933567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.
    Hijazi Z; Hohnloser SH; Oldgren J; Andersson U; Connolly SJ; Eikelboom JW; Ezekowitz MD; Reilly PA; Siegbahn A; Yusuf S; Wallentin L
    Circulation; 2014 Mar; 129(9):961-70. PubMed ID: 24323795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial.
    Easton JD; Lopes RD; Bahit MC; Wojdyla DM; Granger CB; Wallentin L; Alings M; Goto S; Lewis BS; Rosenqvist M; Hanna M; Mohan P; Alexander JH; Diener HC;
    Lancet Neurol; 2012 Jun; 11(6):503-11. PubMed ID: 22572202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
    Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
    Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
    Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
    Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patients With Atrial Fibrillation Taking Nonsteroidal Anti-Inflammatory Drugs and Oral Anticoagulants in the ARISTOTLE Trial.
    Dalgaard F; Mulder H; Wojdyla DM; Lopes RD; Held C; Alexander JH; De Caterina R; Washam JB; Hylek EM; Garcia DA; Gersh BJ; Wallentin L; Granger CB; Al-Khatib SM
    Circulation; 2020 Jan; 141(1):10-20. PubMed ID: 31747786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Alexander JH; Lopes RD; Thomas L; Alings M; Atar D; Aylward P; Goto S; Hanna M; Huber K; Husted S; Lewis BS; McMurray JJ; Pais P; Pouleur H; Steg PG; Verheugt FW; Wojdyla DM; Granger CB; Wallentin L
    Eur Heart J; 2014 Jan; 35(4):224-32. PubMed ID: 24144788
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Hijazi Z; Siegbahn A; Andersson U; Granger CB; Alexander JH; Atar D; Gersh BJ; Mohan P; Harjola VP; Horowitz J; Husted S; Hylek EM; Lopes RD; McMurray JJ; Wallentin L;
    Circulation; 2014 Feb; 129(6):625-34. PubMed ID: 24226808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic Analysis of Apixaban Therapy for Patients With Atrial Fibrillation From a US Perspective: Results From the ARISTOTLE Randomized Clinical Trial.
    Cowper PA; Sheng S; Lopes RD; Anstrom KJ; Stafford JA; Davidson-Ray L; Al-Khatib SM; Ansell J; Dorian P; Husted S; McMurray JJV; Steg PG; Alexander JH; Wallentin L; Granger CB; Mark DB
    JAMA Cardiol; 2017 May; 2(5):525-534. PubMed ID: 28355434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apixaban versus warfarin in patients with atrial fibrillation.
    Granger CB; Alexander JH; McMurray JJ; Lopes RD; Hylek EM; Hanna M; Al-Khalidi HR; Ansell J; Atar D; Avezum A; Bahit MC; Diaz R; Easton JD; Ezekowitz JA; Flaker G; Garcia D; Geraldes M; Gersh BJ; Golitsyn S; Goto S; Hermosillo AG; Hohnloser SH; Horowitz J; Mohan P; Jansky P; Lewis BS; Lopez-Sendon JL; Pais P; Parkhomenko A; Verheugt FW; Zhu J; Wallentin L;
    N Engl J Med; 2011 Sep; 365(11):981-92. PubMed ID: 21870978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.